Literature DB >> 17904652

Re-emergence of striatal cholinergic interneurons in movement disorders.

Antonio Pisani1, Giorgio Bernardi, Jun Ding, D James Surmeier.   

Abstract

Twenty years ago, striatal cholinergic neurons were central figures in models of basal ganglia function. But since then, they have receded in importance. Recent studies are likely to lead to their re-emergence in our thinking. Cholinergic interneurons have been implicated as key players in the induction of synaptic plasticity and motor learning, as well as in motor dysfunction. In Parkinson's disease and dystonia, diminished striatal dopaminergic signalling leads to increased release of acetylcholine by interneurons, distorting network function and inducing structural changes that undoubtedly contribute to the symptoms. By contrast, in Huntington's disease and progressive supranuclear palsy, there is a fall in striatal cholinergic markers. This review gives an overview of these recent experimental and clinical studies, placing them within the context of the pathogenesis of movement disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904652     DOI: 10.1016/j.tins.2007.07.008

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  182 in total

1.  Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors:  Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-12-01       Impact factor: 4.030

2.  Opioidergic interactions between striatal projection neurons.

Authors:  Craig P Blomeley; Enrico Bracci
Journal:  J Neurosci       Date:  2011-09-21       Impact factor: 6.167

3.  Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.

Authors:  Jayms D Peterson; Joshua A Goldberg; D James Surmeier
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

4.  AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.

Authors:  Jacob Bendor; José E Lizardi-Ortiz; Robert I Westphalen; Markus Brandstetter; Hugh C Hemmings; David Sulzer; Marc Flajolet; Paul Greengard
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

5.  Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.

Authors:  Gregory J Digby; Meredith J Noetzel; Michael Bubser; Thomas J Utley; Adam G Walker; Nellie E Byun; Evan P Lebois; Zixiu Xiang; Douglas J Sheffler; Hyekyung P Cho; Albert A Davis; Natali E Nemirovsky; Sarah E Mennenga; Bryan W Camp; Heather A Bimonte-Nelson; Jacob Bode; Kimberly Italiano; Ryan Morrison; J Scott Daniels; Colleen M Niswender; M Foster Olive; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

6.  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Authors:  Marta Garcia-Miralles; Michal Geva; Jing Ying Tan; Nur Amirah Binte Mohammad Yusof; Yoonjeong Cha; Rebecca Kusko; Liang Juin Tan; Xiaohong Xu; Iris Grossman; Aric Orbach; Michael R Hayden; Mahmoud A Pouladi
Journal:  JCI Insight       Date:  2017-12-07

7.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.

Authors:  G Martella; P Platania; D Vita; G Sciamanna; D Cuomo; A Tassone; A Tscherter; T Kitada; P Bonsi; J Shen; A Pisani
Journal:  Exp Neurol       Date:  2008-11-21       Impact factor: 5.330

8.  Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia.

Authors:  Gersilene Valente de Oliveira; Patrícia Xavier Lima Gomes; Fernanda Yvelize Ramos de Araújo; Silvânia Maria Mendes Vasconcelos; Hélio Vitoriano Nobre Júnior; Francisca Cléa Florenço de Sousa; David F de Lucena; Thomas N Hyphantis; André Férrer Carvalho; Danielle Silveira Macêdo
Journal:  Metab Brain Dis       Date:  2012-10-25       Impact factor: 3.584

Review 9.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

10.  Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson's disease.

Authors:  X Zhang; Z-J Feng; K Chergui
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.